San Francisco-based Nektar Therapeutics (NASDAQ: [[ticker:NKTR]]) said today it has raised $220 million in net proceeds through a public offering of stock. The company agreed to sell 19 million shares of new stock, and has granted its underwriter the option to buy another 2.85 million more shares to cover over-allotments. Jefferies & Co. acted as the sole book-running manager of the deal.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
